Clinical trials: BPH
Benign Prostate Hypertrophy(BPH)
Suprapubic Cystostomy as an Adjunct to Monopolar Transurethral Enucleation of the Prostate
SPC use has previously been evaluated in monopolar transurethral enucleation and resection of the prostate (M-TUERP) compared with bipolar TURP [10].
- Trial name
- NCT07841964
- Testing
- Monopolar transurethral enucleation of the prostate without suprapubic cystostomy, Monopolar transurethral enucleation of the prostate with suprapubic cystostomy
- Where
- Egypt
- Volunteers
- 160 people
- Sponsor
- Beni-Suef University
Benign Prostatic Hyperplasia, BPH
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Conditions
- Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
- Trial name
- NCT01846793
- Testing
- NX-1207
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- Nymox Corporation
Benign Prostatic Hyperplasia
QUAPELLA (QUAlity of Prostate Enucleation by LUMENIS - Laser)
This observational study aims at describing the learning curve of the Holmium Enucleation of the Prostate (HoLEP) technique using a LUMENIS laser device by senior attending urologists.
- Trial name
- QUAPELLA (NCT01534793)
- Testing
- Holmium Laser Enucleation of the Prostate (HoLEP)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)
Benign prostatic hyperplasia (BPH) is a very common pathology of the aging man with an incidence that rises from 40% in men aged 50 to 60 years to 90% in men over 80 years.
- Trial name
- SOAP (NCT03297281)
- Testing
- Maintenance of OAC in surgery of BPH by PVP., Discontinuation of OAC in surgery of BPH by PVP.
- Where
- France
- Volunteers
- 389 people
- Sponsor
- Clinique Pasteur
Benign Prostatic Hyperplasia, Prostate Cancer
Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate
Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended.
- Trial name
- NCT02822963
- Where
- Taiwan
- Sponsor
- National Cheng-Kung University Hospital
PSA Changes After TURP
Serum Prostatic Specific Antigen Changes After Bipolar and Monopolar TURP
To use PSA levels after bipolar and monopolar transurethral resection of the benign prostatic hyperplasia as an indicator of the quality of resection .
- Trial name
- NCT05533047
- Testing
- TURP
- Volunteers
- 2 people
- Sponsor
- Assiut University
Prostatic Hyperplasia, Hypertension
Does Benign Prostatic Obstruction Cause Hypertension?
The known correlation between benign prostatic hypertrophy (BPH) and hypertension could be explained by 3 theoretical pathway models.
- Trial name
- NCT02347436
- Testing
- 24-hr ambulatory blood pressure measurement
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- St. Olavs Hospital
Benign Prostatic Hyperplasia
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg…
- Trial name
- NCT00540124
- Testing
- Tadalafil, Tamsulosin
- Where
- 5 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Prostatic Hyperplasia
Prospective Sexual Function Study for BPH Subjects
This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo.
- Trial name
- NCT01777269
- Testing
- Dutasteride plus tamsulosin
- Where
- 67 sites in Australia, France and 5 more
- Volunteers
- 489 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia, Prostate Cancer
Digital Rectal Exam Proficiency Tool
A digital rectal exam proficiency tool, titled the 'DiRECT' was developed based on the consensus of 10 experts. The purpose of this study is to validate this tool for use in both undergraduate and graduate medical education .
- Trial name
- DiRECT (NCT02278679)
- Testing
- Digital Rectal Exam
- Where
- United States
- Volunteers
- 410 people
- Sponsor
- University of Virginia
Erectile Dysfunction, Benign Prostatic Hyperplasia
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil 25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract symptoms (LUTS) associated with benign…
- Trial name
- NCT01967251
- Testing
- Udenafil
- Where
- 8 sites in Mexico
- Sponsor
- Takeda
Prostatic Hyperplasia
Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
- Trial name
- FDC114785 (NCT01673490)
- Testing
- Dutasteride/Tamsulosin
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Atherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH)
Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
- Trial name
- NCT07196280
- Testing
- 5-Alpha Reductase Inhibitors
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Urologic Neoplasms, Benign Prostatic Hyperplasia
Spinal Versus General Anesthesia in Open Simple Prostatectomy
Open simple prostatectomy is still performed for selected patients with benign prostatic hyperplasia, particularly in cases with large prostate volume.
- Conditions
- Urologic Neoplasms, Benign Prostatic Hyperplasia, Anesthesia
- Trial name
- NCT07643415
- Testing
- Spinal anesthesia, General anesthesia
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Hitit University
Benign Prostatic Hyperplasia, Bladder Outlet Obstruction
Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia
This study will evaluate the safety and effectiveness of different surgical treatments for men with small-volume benign prostatic hyperplasia (BPH).
- Conditions
- Benign Prostatic Hyperplasia, Bladder Outlet Obstruction, Lower Urinary Tract Symptoms (LUTS)
- Trial name
- ThuLEP-BNI (NCT07569874)
- Testing
- Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision, Thulium Laser Enucleation of the Prostate, Transurethral Resection of the Prostate
- Where
- China
- Volunteers
- 932 people
- Sponsor
- Chinese PLA General Hospital
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.
Background: Patients with indwelling urinary catheter for chronic retention due to obstructive BPH refractory to medical therapy are candidates for prostatectomy still considered as the gold standard of treatment.
- Trial name
- Prost-EMBOL (NCT01931605)
- Testing
- Prostatic arterial embolization using BeadBlock (Terumo)
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Rouen
Benign Prostatic Hyperplasia
Waterjet Prostate Ablation
Introduction Men with enlarged prostates commonly experience lower urinary tract symptoms and may go on to develop complications such as acute urinary retention (AUR).
- Trial name
- NCT03938194
- Testing
- Aquablation
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Prostate Hyperplasia
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of…
- Trial name
- NCT02244294
- Testing
- FLOMAX® capsules
- Volunteers
- 176 people
- Sponsor
- Boehringer Ingelheim